低剂量口服甲氨蝶呤治疗多发性硬化症：一项试点研究。
Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.
作者信息
Currier R D, Haerer A F, Meydrech E F
机构信息
Department of Neurology, University of Mississippi Medical Center, Jackson 39216.
出版信息
J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1217-8. doi: 10.1136/jnnp.56.11.1217.
Abstract
An 18-month double-blind treatment of multiple sclerosis with low dose oral methotrexate showed it to be well tolerated and suggested effectiveness in exacerbating-remitting MS but not in the exacerbating progressive and chronic progressive stages.
摘要
一项为期18个月的低剂量口服甲氨蝶呤治疗多发性硬化症的双盲试验表明，该药物耐受性良好，对复发缓解型多发性硬化症有疗效，但对继发进展型和慢性进展型无效。
相似文献
1
Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.低剂量口服甲氨蝶呤治疗多发性硬化症：一项试点研究。
J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1217-8. doi: 10.1136/jnnp.56.11.1217.
2
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.低剂量（7.5毫克）口服甲氨蝶呤可降低慢性进展性多发性硬化症的进展速度。
Ann Neurol. 1995 Jan;37(1):30-40. doi: 10.1002/ana.410370108.
3
Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs.低剂量口服甲氨蝶呤治疗慢性进行性多发性硬化症：系列磁共振成像分析
Neurology. 1996 Nov;47(5):1153-7. doi: 10.1212/wnl.47.5.1153.
4
5
A systematic review of oral methotrexate for multiple sclerosis.口服甲氨蝶呤治疗多发性硬化症的系统评价
Mult Scler. 2006 Aug;12(4):507-10. doi: 10.1191/1352458506ms1299oa.
6
Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.低剂量（7.5毫克）口服甲氨蝶呤治疗慢性进展性多发性硬化症。一项随机、安慰剂对照试验的设计，样本量受益于一个综合结局变量，包括毒性的初步数据。
Online J Curr Clin Trials. 1992 Sep 25;Doc No 19:[7723 words; 89 paragraphs].
7
Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.甲基泼尼松龙治疗多发性硬化症：等效高剂量口服与静脉治疗的比较
J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1219-20. doi: 10.1136/jnnp.56.11.1219.
8
Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1.用共聚物-1对复发缓解型多发性硬化症进行实验性治疗。
Ann Neurol. 1994;36 Suppl:S115-7. doi: 10.1002/ana.410360727.
9
Biased assessment of blinding in a randomized placebo-controlled trial of oral methotrexate in chronic progressive multiple sclerosis.口服甲氨蝶呤治疗慢性进行性多发性硬化症的随机安慰剂对照试验中对盲法的偏倚评估。
Ann Neurol. 1995 Nov;38(5):832-3. doi: 10.1002/ana.410380521.
10
A placebo-controlled trial of isoprinosine in patients with multiple sclerosis.一项针对多发性硬化症患者的异搏定安慰剂对照试验。 （注：原文中的“isoprinosine”一般译为“异丙肌苷” ，这里根据你要求不能添加解释就按你提供英文单词直接翻译了，实际医学领域一般用标准译名“异丙肌苷” 。）
J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):164-8. doi: 10.1136/jnnp.57.2.164.
引用本文的文献
1
Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.鞘内注射甲氨蝶呤治疗进展性多发性硬化症：一项长期随访的1期开放标签研究。
J Neurol. 2025 May 4;272(5):374. doi: 10.1007/s00415-025-13114-z.
2
Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.多发性硬化症合并自身免疫性疾病患者的治疗方法。
Ther Adv Neurol Disord. 2021 Aug 23;14:17562864211035542. doi: 10.1177/17562864211035542. eCollection 2021.
3
A narrative review of psoriasis and multiple sclerosis: links and risks.银屑病与多发性硬化症的叙述性综述：联系与风险
Psoriasis (Auckl). 2019 Aug 22;9:81-90. doi: 10.2147/PTT.S186637. eCollection 2019.
4
[Cell depletion and myoablation for neuroimmunological diseases].[用于神经免疫疾病的细胞清除和肌消融]
Nervenarzt. 2016 Aug;87(8):814-20. doi: 10.1007/s00115-016-0156-3.
5
Phase II trial of methotrexate in myasthenia gravis.甲氨蝶呤治疗重症肌无力的 II 期临床试验。
Ann N Y Acad Sci. 2012 Dec;1275(1):23-8. doi: 10.1111/j.1749-6632.2012.06804.x.
6
Role of immunosuppressive therapy for the treatment of multiple sclerosis.免疫抑制疗法在多发性硬化治疗中的作用。
Neurotherapeutics. 2013 Jan;10(1):77-88. doi: 10.1007/s13311-012-0172-3.
7
8
Childhood multiple sclerosis: a review.儿童多发性硬化症：综述
Ment Retard Dev Disabil Res Rev. 2006;12(2):147-56. doi: 10.1002/mrdd.20105.
9
[The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].
Nervenarzt. 2005 Jun;76(6):740-7. doi: 10.1007/s00115-005-1885-x.
10
Methotrexate for multiple sclerosis.甲氨蝶呤用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2004;2004(2):CD003208. doi: 10.1002/14651858.CD003208.pub2.
本文引用的文献
1
A new scale for evaluating disability in multiple sclerosis.一种评估多发性硬化症残疾程度的新量表。
Neurology. 1955 Aug;5(8):580-3. doi: 10.1212/wnl.5.8.580.
2
Therapeutic trial of immunosuppressive agents in multiple sclerosis.
Neurology. 1972 Dec;22(12):1268-71. doi: 10.1212/wnl.22.12.1268.
Zotero 插件